Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

74.92 +0.75 (+1.00%)
Streaming Delayed Price Updated: 3:22 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,489,676
Open 74.50
Bid (Size) 74.90 (2)
Ask (Size) 74.93 (5)
Prev. Close 74.17
Today's Range 74.02 - 75.49
52wk Range 23.95 - 74.70
Shares Outstanding 141,797,854
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ionis (IONS) Q3 2025 Earnings Call Transcript
Ionis (IONS) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings.
The company easily beat third-quarter expectations and issued guidance that widely topped forecasts. 
Via Investor's Business Daily

Performance

YTD
+116.0%
+116.0%
1 Month
+14.5%
+14.5%
3 Month
+74.3%
+74.3%
6 Month
+136.3%
+136.3%
1 Year
+90.8%
+90.8%

More News

Read More
Alphabet To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Earnings Scheduled For October 29, 2025
Via Benzinga
Ionis reports third quarter 2025 financial results and highlights progress on key programs
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Ionis Pharmaceuticals Earnings Preview
Via Benzinga
Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease
Via Stocktwits
Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares
Via The Motley Fool
31 Analysts Assess Ionis Pharmaceuticals: What You Need To Know
Via Benzinga
Ionis to hold third quarter 2025 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Shows Strong Growth Momentum and Technical Strength
Via Chartmill
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
Via MarketMinute
Why Ionis Stock, Approaching A Six-Year High, Just Snagged A Price-Target Hike
Via Investor's Business Daily
This Penumbra Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
Via Benzinga
Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
From Biogen Inc.
Via GlobeNewswire
What Analysts Are Saying About Ionis Pharmaceuticals Stock
Via Benzinga
Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial
Via Benzinga
Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease
From Ionis Pharmaceuticals, Inc.
Via Business Wire
TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
From Biogen Inc.
Via GlobeNewswire
Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases
From Ionis Pharmaceuticals, Inc.
Via Business Wire

Frequently Asked Questions

Is Ionis Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Ionis Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Ionis Pharmaceuticals, Inc. - Common Stock trade on?
Ionis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock is IONS on the Nasdaq Stock Market
What is the current price of Ionis Pharmaceuticals, Inc. - Common Stock?
The current price of Ionis Pharmaceuticals, Inc. - Common Stock is 74.92
When was Ionis Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Ionis Pharmaceuticals, Inc. - Common Stock was at 10/31/25 03:22 PM ET
What is the market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock is 10.62B
How many shares of Ionis Pharmaceuticals, Inc. - Common Stock are outstanding?
Ionis Pharmaceuticals, Inc. - Common Stock has 11B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.